More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are nearly 35 technology platforms for the development of BBB penetrant drugs, claims Roots Analysis

The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.

 


To order this 400+ page report, which features 145+ figures and 205+ tables, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:

§  Type of Payment Model Adopted

§  Upfront payments

§  Milestone payments

 

§  Type of Molecule

§  Small Molecules

§  Biologics

 

§  Target Disease Indication

§  Brain Metastases in Breast Cancer

§  Glioblastoma Multiforme

§  Hunter Syndrome

§  Hurler Syndrome

 

§  Leading Technology Platforms

§  G®-Technology

§  J-Brain Cargo® Technology

§  LRP-1 Technology

§  Trojan Horse Technology

 

§  Leading Drug Developers

§  2-BBB

§  Angiochem

§  ArmaGen

§  JCR Pharmaceuticals

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

 

 

The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics report features the following companies, which we identified to be key players in this domain:

§  Angiochem

§  ArmaGen

§  BioArctic

§  Cyclenium Pharma

§  Denali Therapeutics

§  ICB International

§  Iproteos

§  JCR Pharmaceuticals

§  Lauren Sciences

§  Medesis Pharma

§  Ossianix

§  Vect-Horus

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Landscape: Non-Invasive BBB Penetration

5. Market Landscape: BBB Penetrating Drugs

6. Company Profiles

7. Technology Competitiveness Analysis 

8. Non-Invasive BBB Penetration Technologies: Popular Approaches


9. Partnerships and Collaborations

10. Analysis of Recent Licensing Agreements

11. Funding and Investment Analysis

12. Patent Analysis

13. Drug Development Strategy Analysis

14. Market Potential of Key Neurological Disorders

 

15. Likely Partner Analysis

 

16. Market Forecast

 

17. Conclusion

 

18. Executive Insights

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Location: United States

Comments

Post a Comment

Popular posts from this blog

The on-body drug delivery-related intellectual landscape report identifies and analyzes all relevant IP publications, featuring the contributions of both established and emerging technology developers

Image
Several innovative drug delivery technologies have gathered notable momentum (in terms of adoption and sales) soon after entering the market; most of these are designed to address the unmet needs of administering complex pharmacological interventions Roots Analysis has announced the addition of the “ On-body Drug Delivery Devices - Intellectual Property Landscape: Focus on Popular / Relevant Prior Art Search Expressions, Patent Valuation, Pockets of Innovation / White Spaces, and Key Applicant Profiles ” report to its list of offerings.   Since the early 20th century, over 12,000 patents / patent applications have been granted / filed in relation to drug delivery devices that can either be worn on the body ( or implanted ), by both industry and non-industry players. Presently, innovation in this domain is focused on developing cheaper and more environment friendly drug delivery systems, with provisions to minimize / altogether eliminate the risk of needlestick injuries. ...
Read more

Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

Image
To order this detailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html   Key Inclusions §   A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).  §   A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant paramete...
Read more

The CAR-T cell therapy market is estimated to be worth USD 14 billion in 2030, predicts Roots Analysis

Image
  Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status   Roots Analysis is pleased to announce the publication of its recent study, titled, “ CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030 ”   The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and acade...
Read more